Riverwater Partners LLC Takes $580,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Riverwater Partners LLC acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 5,511 shares of the medical equipment provider’s stock, valued at approximately $580,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Farallon Capital Management LLC increased its position in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock valued at $121,867,000 after buying an additional 394,837 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares in the last quarter. Finally, Swedbank AB grew its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after acquiring an additional 125,843 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 1.8 %

LNTH stock opened at $110.64 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The firm has a market cap of $7.67 billion, a P/E ratio of 16.89 and a beta of 0.50. The company’s 50-day simple moving average is $106.72 and its 200-day simple moving average is $92.23.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.40 EPS. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LNTH shares. B. Riley lifted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Finally, Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Insiders Place Their Bets

In other news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,981 shares of company stock worth $2,689,156. Company insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.